What is the teduglutide dose, and how is the vial mixed?
Every vial at a glance.
| Vial | 0.5 mL of water |
|---|---|
| 5 mg | 10 mg/mL: 2,000 mcg is 20 units, 3,000 mcg is 30 units, 3,600 mcg is 36 units |
The US label gives 0.05 mg/kg once daily by subcutaneous injection for adults and children 1 year of age and older with short bowel syndrome who are dependent on parenteral support, from a 5 mg vial mixed with 0.5 mL of water to 10 mg/mL.1
What the kit holds
The US label supplies 5 mg of teduglutide powder in a single-dose vial, with 0.5 mL Sterile Water for Injection in a prefilled syringe.1 A one-vial kit also holds a separate needle, a 1 mL dosing syringe and four alcohol swabs, and kits are dispensed as one vial or 30 vials.1 The EU product information adds a 1.25 mg vial that gives 2.5 mg/ml in 0.5 ml, for paediatric patients under 20 kg and those aged 4 months to less than 12 months.2 The table's rows come to 0.20 ml, 0.30 ml and 0.36 ml, the EU product information's adult volumes at 38-41 kg, 58-61 kg and 70-73 kg.2
Mixing a 5 mg vial and reading the syringe
The US label says to mix each vial with the 0.5 mL of preservative-free Sterile Water for Injection in the prefilled syringe, giving 10 mg/mL.1 It says not to shake the vial, and not to use a product that stays undissolved after a second attempt.1
3,000 mcg of Teduglutide (GLP-2) from a 5 mg vial mixed with 0.5 mL is 30 units on a U-100 syringe.
Worked example: 3 mg from a 5 mg vial mixed with 0.5 mL is 0.30 mL, or 30 units on a U-100 syringe; 0.30 ml is the EU product information's adult volume at 58-61 kg.2
3,000 mcg of Teduglutide (GLP-2) from a 5 mg vial mixed with 0.5 mL is 30 units on a U-100 syringe.
Dose by weight and what trials used
The US label gives 0.05 mg/kg once daily by subcutaneous injection for adults and pediatric patients 1 year of age and older with short bowel syndrome who are dependent on parenteral support.1 The EU product information gives 0.05 mg/kg body weight once daily for adults with short bowel syndrome who are stable following a period of intestinal adaptation, sets the number of vials by body weight and has the physician weigh the patient each visit.2 Its adult volume table for the 5 mg vial runs from 0.20 ml at 38-41 kg to 0.46 ml at 90-93 kg, with 0.30 ml at 58-61 kg.2
In the Jeppesen trial of 83 patients over 24 weeks, 0.05 mg/kg/day had a significant effect on the graded response score (16/35, p=0.007) and 0.10 mg/kg/day did not (8/32 vs 1/16, p=0.16), against placebo.3
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Jeppesen trial3 | 0.10 mg/kg/day, 0.05 mg/kg/day or placebo, once daily | 83 patients (n=32, 35, 16); the US label gives n=33 on 0.1 mg/kg/day1 | 24 weeks |
| STEPS, Jeppesen 20124 | 0.05 mg/kg/d or placebo, once daily | 86 patients (n=43 per arm)5 | 24 weeks |
| Chiba paediatric studies6 | Open-label 0.05 mg/kg/day; infants in one study randomised to teduglutide or standard of care | Twelve infants and 8 children | 24 weeks, plus a 24-week extension |
Milligram has no logged share for teduglutide that can be shown.
Storage before and after mixing
The US label says one-vial kits and the vials for 30-vial kits are stored refrigerated at 2°C to 8°C before dispensing, then at room temperature up to 25°C with a 90-day "use by" dating after dispensing, and not frozen.1 The EU product information says to store the 1.25 mg vial in a refrigerator (2 °C – 8 °C) and the 5 mg vial below 25 °C, neither frozen, with a shelf life of 4 years unopened.2 Once mixed, it says to administer within 3 hours, discard the unused portion, and not shake or freeze the solution.1 The EU product information shows stability for 3 hours at 25 °C for the 5 mg vial and 24 hours up to 25 °C for the 1.25 mg vial, and for both normally not over 24 hours at 2 to 8 °C, unless reconstitution has taken place in controlled and validated aseptic conditions.2 The two texts do not agree on how long a mixed vial keeps.
Frequently asked questions
Where is teduglutide injected?
The US label says subcutaneous use only, alternating between the 4 quadrants of the abdomen, or alternating thighs or arms.1
Is the dose different with kidney problems?
The US label gives 0.025 mg/kg once daily for adults and children with moderate or severe renal impairment or end-stage renal disease (estimated glomerular filtration rate less than 60 mL/min/1.73 m2).1 The EU product information says the daily dose is to be reduced by 50% in adult or paediatric patients with moderate and severe renal impairment (creatinine clearance less than 50 ml/min) and end-stage renal disease.2
Are there cycles?
Neither the US label nor the EU product information gives an on/off cycle for adults. The EU product information evaluates the effect after 6 months in adults, and in children after 6 months, or 12 weeks below the age of two years; it describes infant extension studies of up to 9 cycles of 24 weeks.2
References
- Takeda (DailyMed). These highlights do not include all the information needed to use GATTEX safely and effectively. See full prescribing information for GATTEX. GATTEX ® (teduglutide) for injection, for subcutaneous use Initial U.S. Approval: 2012. 2025. dailymed.nlm.nih.gov
- EMA. Revestive, INN-teduglutide. ema.europa.eu
- PMC. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. 2011. pmc.ncbi.nlm.nih.gov
- PubMed. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. 2012. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT00798967: Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects. 2012. clinicaltrials.gov
- PMC. Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support. 2023. pmc.ncbi.nlm.nih.gov